Gritstone bio, Inc. (NASDAQ:GRTS – Get Rating) insider Vassiliki Economides acquired 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were bought at an average price of $1.90 per share, with a total value of $22,800.00. Following the acquisition, the insider now directly owns 214,058 shares of the company’s stock, valued at approximately $406,710.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Gritstone bio Stock Down 5.7 %
Shares of GRTS stock opened at $1.66 on Friday. The firm’s 50 day moving average is $2.47 and its 200 day moving average is $2.82. Gritstone bio, Inc. has a 12 month low of $1.65 and a 12 month high of $5.85. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.27 and a current ratio of 6.27.
Gritstone bio (NASDAQ:GRTS – Get Rating) last posted its earnings results on Thursday, March 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. The firm had revenue of $4.26 million for the quarter, compared to the consensus estimate of $3.08 million. Gritstone bio had a negative return on equity of 81.55% and a negative net margin of 820.91%. As a group, research analysts expect that Gritstone bio, Inc. will post -1.2 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on GRTS shares. Evercore ISI assumed coverage on shares of Gritstone bio in a research note on Friday, March 31st. They set an “outperform” rating for the company. B. Riley assumed coverage on Gritstone bio in a report on Tuesday, March 28th. They set a “buy” rating and a $8.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Gritstone bio in a research note on Tuesday, March 14th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.75.
Gritstone bio Company Profile
Gritstone bio, Inc clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
- Get a free copy of the StockNews.com research report on Gritstone bio (GRTS)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Gritstone bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone bio and related companies with MarketBeat.com's FREE daily email newsletter.